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Abstract: Presently, adenovirus-based vaccines are dosed by viral particle or viral genome number. Given
that the ratio of these to the actually infectious units, the active principle of the vaccines, can vary by
several orders of magnitudes in a given preparation this is criticized by the author as inappropriate.
Based on existing data from both, animal as well as human vaccination trials, the commentary details
this problem and proposes solutions to the problem.
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Dear Editor,
Since more than a year our world is in the grip of the 
COVID-19 pandemic. The necessary measures to reduce 
the incidence of infection have an enormous impact on our 
daily life. The way out appears to be an efficient vaccination 
campaign.
With unprecedented speed an impressive array of differ-
ent vaccines has been developed and tested during the last 
year. These vaccines are based on different technological 
platforms, but converge in the strategy to elicit an immune 
response against the viral spike protein from the viral enve-
lope that interacts with the angiotensin converting enzyme 
2 (ACE2) protein on the surface of host cells to initiate their 
infection (Forni et al. 2021).
Classical approaches for vaccination, like the application 
of glutaraldehyde-inactivated viruses or purified recombi-
nant spike protein, have been used with moderate success. 
However, some of the more innovative approaches that aim 
to reprogram body cells to produce the S1 protein for sub-
sequent presentation to the immune system have turned out 
to be much more successful. Of these, the direct injection 
of spike protein-coding mRNA formulated as lipid nano-
particles to ensure sufficient stability and efficient uptake 
by host cells has demonstrated enormous efficacy. Comir-
naty (BioNTech/Pfizer) and Spikevax (Moderna), the two 
mRNA-based vaccines that have obtained full market 
authorization in Switzerland and emergency authorization 
in many other countries, have both impressed with an effi-
cacy of around 95% in preventing the infection (Baden et al. 
2021; Polack et al. 2020). Likewise, the adenovirus-based 
vaccine Sputnik V (Gamaleya Research Institute) is reported 
to afford > 90% protection from infection (Logunov et al. 
2020). Somewhat more disappointing were the reports for 
Vaxzevria (AstraZeneca), the Chimpanzee adenovirus-based 
vaccine meanwhile widely in use, with a reported protection 
efficacy between 60 and 90%, depending on the study (Voy-
sey et al. 2021). Surprisingly, the counterintuitive observa-
tion was made that in a cohort that received a lower dose for 
the priming injection, a higher efficacy was obtained. What 
may be the reason for such an unexpected result? One expla-
nation that has been put forward is a potential immunity 
against the vector, arising after the first immunization, that 
may simply be less pronounced with a lower initial dose. In 
turn, the booster injection may be more efficacious if the first 
dose was low. Alternatively, it could just be a false-positive 
result, a statistical outlier. However, an—in my personal 
view—very likely explanation has so far been overlooked. I 
will elaborate on that in the following.
A close look at the dosing regimen in the Vaxzevria clini-
cal trials reveals that it is based on the number of viral parti-
cles: the standard dose applied per shot is 5 ×  1010 particles, 
as determined by either quantification of viral protein or 
viral genomes (Voysey et al. 2021). However, the produc-
tion of infectious adenovirus particles in HEK293 cells, the 
procedure widely applied for virus production, including 
the production of Vaxzevria, is a process that is difficult to 
standardize with respect to the final yield. Unfortunately, 
the percentage of viral particles that are actually infectious, 
i.e., those that can elicit an immune response against the 
recombinant protein they code for, can vary by orders of 
magnitudes. Tatsis and colleagues have reported that in their 
hands, several different Chimpanzee adenovirus-derived 
constructs showed batch-to-batch variations in the ratio of 
viral particles to infectious units by more than two orders 
of magnitudes (Tatsis et al. 2006). Thus, the particle (or 
genome) number is no adequate parameter for the estima-
tion of the active principle, the infectious units, inside of an 
adenoviral preparation.
In fact, when the backbone of the adenoviral vector finally 
used in Vaxzevria was developed, the authors paid attention 
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to this fact and analyzed the relation of immune response 
to the viral dose, either defined by particle number or by 
infectious units (Dicks et al. 2012). When testing two dif-
ferent patches that differed substantially in their particle-
to-infectious-units ratio (6.7 versus 48), they observed that 
dosing by viral particles produced a significantly different 
immune response in favor of the batch enriched in infec-
tious units (Fig. 1), while dosing by infectious units pro-
duced an almost equal response for both batches (Fig. 2). 
Further analysis of their data reveals a clear dose–response 
when the immune response is plotted against the number of 
infectious units (Fig. 3). This substantiates that the active 
principle inside the preparation is the infectious virus and 
that its quantity is the relevant parameter for a proper dosing. 
That the dose–response is an important issue in human vac-
cination has nicely been demonstrated in the clinical phase I 
trial of Spikevax (Fig. 4), indicating that lower doses lead to 
substantially lower immune responses (Jackson et al. 2020).
Coming back to Vaxzevria and the apparent discrepancy 
between dosing schemes and efficacy, a likely explanation in 
view of the above facts is that batch differences in the ratio 
of viral particles to infectious units are the reason for the 
unexpected outcome, and that the improper dose adjustment 
to viral particles/genomes produces variable immunization 
results.
Why then has viral particle number been chosen as the 
basis for the dosing? Looking closer at other adenoviral vac-
cines, for instance Sputnik V and the Janssen COVID-19 
Fig. 1  Immune response to an adenoviral vaccine, dosing based on 
viral particles. Immune responses were measured after intramuscular 
injection of  107 adenoviral particles in Balb/c mice using two differ-
ent batches of the same adenoviral construct. Batch A had a viral par-
ticle-to-infectious units ratio of 6.67, batch B had a viral particle-to-
infectious units ratio of 47.88. Four mice were tested per batch. Data 
are given as mean ± SEM. The difference in the immune responses to 
the two batches was statistically significant (p = 0.013 in a one-sided 
students T-test). Data are  taken from Dicks et al. (2012)
Fig. 2  Immune response to an adenoviral vaccine, dosing based on 
infectious units. The same experimental paradigm and virus prepara-
tions as in Fig. 1 were used, with the single exception that the doses 
applied were  107 infectious units, rather than viral particles. The dif-
ference in the immune responses to the two batches were not statisti-
cally significant (p = 0.250 in a one-sided students T-test). Data are 
taken from Dicks et al. (2012)
Fig. 3  Dose response to an adenoviral vaccine, based on infectious 
units. Data from Fig.  1 and 2, for the sake of simplicity fitted to 
Michaelis–Menten equation (r2 = 0.892)
Fig. 4  Dose response to an mRNA vaccine in a human clinical trial. 
Antibody titer in human blood sera as measured by an ELISA using 
the P2-variant of the spike protein (forced open conformation) as the 
antigen after immunization of healthy human individuals (n = 15). 
Immune responses were measured 4 weeks after the first (closed cir-
cles) or second (open circles) immunization. The dotted line indicates 
the geometric mean of data obtained from sera of COVID-19 patients 
after recovery. The data are  taken from the phase I clinical trial of 
Spikevax (Jackson et  al. 2020). Fitting the curves to the Michaelis–
Menten equation resulted in r2 of 0.996 and 0.999 for the first and 
second immunization, respectively
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vaccine (Logunov et al. 2020), their dosing is also based on 
viral particles. The reason for this collective—in my view 
inappropriate—adjustment is found in the legal framework: 
the European Pharmacopoeia states in its chapter 5.14 Gene 
transfer medicinal products for human use at the end of the 
passage specifying the requirements for Adenovirus vec-
tors for human use under the heading Labelling: “The label 
states: … the recommended human dose, expressed in vector 
particle concentration; …”. This, in my personal opinion, is 
a highly unfortunate mistake. It appears that also the vaccine 
producing companies have meanwhile realized that dosing 
according to viral particles is not appropriate, and at least 
in the EU, the dosing is now given in infectious units, at 
least for Vaxzevria and the Janssen adenovirus-based vac-
cine, stating that at least 2.5 ×  108 (Vaxzevria (EMA_prod-
uct_information_Vaxzevria 2021)) or 8.92  log10 (= 8.3 ×  10
8; 
Janssen vaccine (EMA_product_information_Janssen_vac-
cine 2021)) infectious units must be applied per dose. How-
ever, this still equals to a maximum ratio of viral particles to 
infectious units of 200 (Vaxzevria) or 60 (Janssen vaccine). 
Unfortunately, the clinical trials of both companies were 
based on viral particle number, 5 ×  1010 per dose for both 
vaccines, without specifying the exact particle-to-infectious 
units ratio. Thus, we have no precise idea of the efficacy 
of the now defined minimal doses, and the content of the 
active principle of these vaccines may vary by a factor of 
40 (Vaxzevria) or 12 (Janssen vaccine) if we take 5 as the 
lowest achievable ratio of viral particles to infectious units 
(reasonable estimate based on the data of Tatsis et al. (2006) 
and Dicks et al. (2012)). In my view, this is not acceptable. 
We would never tolerate a similar variability in the potency 
of ordinary medications, such as antibiotics, and we should 
aim for the same standards in the vaccines that we develop 
to save the world from the grip of the COVID pandemic. I 
therefore propose to change the wording in the chapter 5.14 
of the European Pharmacopoeia to “…-the recommended 
dose, expressed in infectious units; …”. Furthermore, it 
might be informative to reanalyze the clinical trials and/
or the postmarketing data of the adenovirus-based vac-
cines to gain a better understanding of the actual correla-
tion between infectious units-based dosing and protection 
efficacy. I would hope to see that the achievable efficacy 
may well exceed the 90% if dosing is done properly, render-
ing adenoviral COVID vaccines valuable contributors to the 
defeat of the pandemic.
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